Weight normativity in action
The entry of glucagon-like peptide-1 (GLP-1) agonists, of which semaglutide is the most widely known, has changed the dialogue surrounding the use of anti-obesity medications. There is increasing demand for semaglutide in Canada even though there are still outstanding questions about its safety,
Authors
- Joel Lexchin (ORCID: https://orcid.org/0000-0001-5120-8029)
- Annemarie Jutel (ORCID: https://orcid.org/0000-0001-7131-3838)
Institutions
- Canadian Institutes of Health Research (CA)
- Victoria University of Wellington (NZ)
Publication Details
- Journal
- Canadian Family Physician
- Published
- 2025-02-01
- DOI
- https://doi.org/10.46747/cfp.710285
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29